GlassScriptPhysician profile
Rachel Koller
NPI 1093552655
$1,227.42
in general payments reported to CMS, 2019-2025
14 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $579 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $267.99 | 2025 | Xospata, Cresemba |
| E.R. Squibb & Sons, L.L.C. | $261.62 | 2024 | Reblozyl |
| Lilly USA, LLC | $184.38 | 2024-2025 | Jaypirca |
| Astrazeneca Pharmaceuticals LP | $126.45 | 2024-2025 | Calquence |
| Sobi, INC | $60.90 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $58.48 | 2025 | |
| Daiichi Sankyo INC. | $58.05 | 2024-2025 | Enhertu, Vanflyta |
| Celgene Corporation | $33.85 | 2025 | Reblozyl |
| Abbvie INC. | $33.49 | 2025 | |
| Beigene USA, INC. | $31.33 | 2024 | Brukinsa |
| Glaxosmithkline, LLC. | $30.07 | 2024 | Ojjaara |
| Incyte Corporation | $28.74 | 2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $26.52 | 2024 | Iclusig |
| Merck Sharp & Dohme LLC | $25.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Koller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.